Multisystem Inflammatory Syndrome in Children during the COVID-19 Pandemic: A Case Report on Managing the...

Area of Science:

• Pediatrics
• Infectious Diseases
• Cardiology

Background:

• The COVID-19 pandemic caused by SARS-CoV-2 has led to a new pediatric inflammatory condition, Multisystem Inflammatory Syndrome in Children (MIS-C).
• MIS-C shares features with Kawasaki disease and toxic shock syndrome, characterized by prolonged fever and hyperinflammation.
• The condition occurs temporally with SARS-CoV-2 spread in communities.

Purpose of the Study:

• To describe the clinical presentation, characteristics, and management of MIS-C in a pediatric patient.
• To highlight a multidisciplinary approach to managing severe hyperinflammation and coronary artery aneurysms in MIS-C.

Main Methods:

• Case report of an 11-year-old boy with MIS-C.
• Detailed description of clinical findings, including prolonged fever, elevated inflammatory markers, and coronary artery aneurysm.
• Multidisciplinary team management utilizing intravenous immunoglobulin, methylprednisolone, and anakinra.

Main Results:

• The patient presented with prolonged fever, marked hyperinflammation, and early, profound coronary artery aneurysm.
• The multidisciplinary treatment strategy involving intravenous immunoglobulin, methylprednisolone, and anakinra was implemented.
• This therapeutic approach was effective in managing the hyperinflammatory disease process.

Conclusions:

• MIS-C is a serious hyperinflammatory condition in children associated with SARS-CoV-2 infection.
• Prompt, aggressive, multidisciplinary management is crucial for addressing severe manifestations like coronary artery aneurysms.
• Combination therapy including anakinra may be a valuable strategy for managing MIS-C.